Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination

Nishiguchi, Yamato; Matsuyama, Hirofumi; Maeda, Kuniko; Shindo, Akihiro; Tomimoto, Hidekazu

doi:10.1186/s12883-021-02489-x

BMC Neurology

Table.1 Clinical characteristics of published cases of Guillain–Barré syndrome/Miller Fisher syndrome following COVID-19 vaccination

From: Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination

Case No.	Age, Sex	Symptoms limb weakness	Paraesthesia	FD	OP	RF	Other neurological signs	Diagnosis	AGA	Comorbidies, Underlying disease	Treatment	Vaccine type	Time to symptom onset	Reference No.
1	54,M		+	+				GBS	negative	nothing	oral PSL	Oxford–AstraZeneca	12 days	[5]
2	20,M		+	+			headache	GBS	negative	ulcerative colitis	oral PSL	Oxford–AstraZeneca	21 days	[5]
3	57,M	+	+	+	+		dysarthria	GBS	negative	asthma, osteoarthritis	IVIg	Oxford–AstraZeneca	11 days	[5]
4	55,M		+	+				GBS	negative	HTN	nothing	Oxford–AstraZeneca	22 days	[5]
5	66,M		+	+			tongue numbness, ataxic gait	BFP	negative	n.d.	IVIg	Oxford–AstraZeneca	7 days	[1]
6	43,M			+			neck pain, urinary retention,dysphagia	BFP	negative	n.d.	IVIg	Oxford–AstraZeneca	11 days	[1]
7	51,M		+	+			leg pain	BFP	GM3(+)	n.d.	nothing	Oxford–AstraZeneca	7 days	[1]
8	71,F	+		+			back pain, abdominal pain, altered taste	BFP	negative	COVID-19 (47 days ago)	nothing	Oxford–AstraZeneca	12 days	[1]
9	53,M		+	+			back pain	BFP	n.d.	n.d.	nothing	Oxford–AstraZeneca	8 days	[1]
10	32,M		+	+			dysphagia, headache, dysarthria	GBS	n.d.	GBS (14 years ago)	IVIg, PP	vector-based vaccine	8 days	[6]
11	62,F	+	+			+	dysarthria, dysphagia	GBS	n.d.	bronchiectasis, asthma, osteoporosis, migraine	IVIg, MV	Oxford–AstraZeneca	8 days	[7]
12	74,M	+		+			back pain, urinary retention, dysarthria	AIDP, ITP	n.d.	HTN, gout, HL, cardiomyopathy	IVIg, PP, PSL	Moderna	13 days	[8]
13	43,F	+		+		+	back pain	GBS	n.d.	n.d.	IVIg, MV	Oxford–AstraZeneca	10 days	[9]
14	67,F	+	+	+		+	dysphagia	GBS	negative	n.d.	IVIg, PP, MV	Oxford–AstraZeneca	14 days	[9]
15	53,F	+	+	+		+	tongue numbness, back pain	GBS	negative	n.d.	IVIg, MV	Oxford–AstraZeneca	12 days	[9]
16	68,F	+	+	+		+	dysphagia, facial numbness	GBS	negative	n.d.	IVIg, MV	Oxford–AstraZeneca	14 days	[9]
17	70,M		+	+		+	bulbar palsy	GBS	n.d.	n.d.	IVIg, MV	Oxford–AstraZeneca	11 days	[9]
18	69,F		+	+	+		bulbar palsy	GBS	n.d.	n.d.	IVIg, PP	Oxford–AstraZeneca	12 days	[9]
19	69,F		+	+		+	bulbar palsy	GBS	n.d.	n.d.	IVIg, MV	Oxford–AstraZeneca	13 days	[9]
20	60,F		+		+		back and legs pain, headache, vomiting	GBS	negative	migraine	IVIg	Johnson & Johnson	10 days	[10]
21	59,M		+	+			postural instability	GBS	negative	HTN, hyperuricemia	IVIg	Oxford–AstraZeneca	10 days	[11]
22	37,M	+	+				back pain	GBS	n.d.	nothing	IVIg	Oxford–AstraZeneca	14 days	[12]
23	73,M	+						GBS	n.d.	HTN, RA	IVIg	Pfizer/BioNTech	16 ~ 17 days	[4]
24	82,F		+				difficulty walking	GBS	n.d.	nothing	IVIg	Pfizer/BioNTech	7 days	[13]
25	71,M				+		headache, ocular pain, ptosis, ataxia	MFS	negative	DM	IVIg	Pfizer/BioNTech	18 days	our case

GBS Guillain-Barre syndrome, MFS Miller Fisher syndrome, COVID-19 Coronavirus disease 2019, FD Facial diplegia, OP Ophthalmoplegia, RF Respiratory failure, AGA Anti-ganglioside antibodies, GM3 Anti-GM3 antibody, AIDP Acute inflammatory demyelinating polyneuropathy, BFP Bifacial weakness with paraesthesias, ITP Immune thrombocytopenia, HTN Hypertension, DM Diabetes mellitus, RA Rheumatoid arthritis, HL Hyperlipidemia, n.d. No data, MV Mechanical ventilation, PP Plasmaphersis, PSL Prednisolone

Back to article page

ISSN: 1471-2377

Contact us

General enquiries: journalsubmissions@springernature.com